Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 50 Solid market leadership position in Japan Japanese modern insulin volume market shares Sanofi Novo Nordisk Eli Lilly Japanese insulin market by segments Device penetration Modern Insulin penetration² tMU CAGR volume¹: -0.8% Penetration 14 12 10 CAGR value¹: -2.7% 100% 70% 60% 80% 50% Fast-acting 00 8 60% 40% 6 4 2 0 Aug 2011 Premix 40% 30% 20% 20% Long-acting 10% 0% 0% Aug 2016 1 CAGR for 5-year period 2 Includes new-generation insulin Source: IMS Monthly MAT August, 2016 volume and value (DKK) figures changing diabetes® Aug 2011 Source: IMS Monthly MAT August, 2016 volume figures 50% 26% 23% Aug 2016 novo nordisk

View entire presentation